Medical Advocates
Lamivudine (Epivir)
 
Perinatal Data

HBV Challenges
HIV Prevention Guidelines
 HIV Pharmacokinetics
 HIV Resistance
 HIV Combination Therapy
Discontinuation
 HIV General Reports
 HIV Adverse Events


 
Lamivudine Main Page Main New/Newsworthy  Home Page      
Last Update:  April 01, 2017
 Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader
HBV Challenges
       
            Journal Papers, Abstracts, and Commentaries
 
  Lamivudine therapy in the treatment of chronic hepatitis B with acute exacerbation during pregnancy.
Hung JH, Chu CJ, Sung PL, et al
 J Chin Med Assoc. 2008 Mar;71(3):155-8.
 Abstract
HIV Prevention Guidelines and Recommendations
United States      
United States

     Internet Documents

  FULL TEXT PDF DOCUMENT
Public Health Service Task Force Recommendations for Use of Antiretroviral Drugs
in Pregnant HIV-Infected Women for Maternal Health and Interventions to Reduce
Perinatal HIV  Transmission in the United States.
Perinatal HIV Guidelines Working Group.
November 2, 2007
Guidelines
 
  FULL TEXT PDF DOCUMENT
Safety and Toxicity of Individual Antiretroviral Agents in Pregnancy
 Perinatal HIV Guidelines Working Group.
November 2, 2007
Guidelines
HIV Pharmacokinetics
       
            Journal Papers, Abstracts, and Commentaries
 
  Pregnancy related effects on Lamivudine Pharmacokinetics: a Population Study with 228 women.
Benaboud S, Tréluyer JM, Urien S, et al
Antimicrob Agents Chemother. 2011 Nov 21
 Abstract

Population Pharmacokinetics of Lamivudine in HIV Exposed and Infected Infants.
Tremoulet AH, Capparelli EV, Patel P, et al 
Antimicrob Agents Chemother. 2007 Sep 24;
 Abstract

FULL-TEXT ARTICLE
 Pharmacokinetics and antiretroviral activity of lamivudine alone or when coadministered
with zidovudine in human immunodeficiency virus type 1-infected pregnant women and
their offspring.
Moodley J, Moodley D, Pillay K, et al.
J Infect Dis 1998 Nov;178(5):1327-33
Paper
HIV Resistance
       
               Conference Reports, Abstracts, and Posters
 
 
Low rate of emergence of nevirapine and lamivudine resistance after post-partum interruption of a
triple-drug regimen.
 Pérez H, Vignoles M, Laufer N, et al
Antivir Ther. 2008;13(1):135-9.
 Abstract
 
High prevalence of primary lamivudine and nelfinavir resistance in HIV-1-infected
pregnant women in the United States, 1998-2004.
 Paredes R, Cheng I, Kuritzkes DR, Tuomala RE. 
AIDS. 2007 Oct 1;21(15):2103-6
 Abstract
 
Low emergence of nevirapine (NVP) and lamivudine (3TC) resistance after
post-partum interruption of a triple drug regimen for prevention of HIV mother
to child transmission (MTCT)
 Pérez H, Vignoles M., Laufer N., Gómez A.
 Abstract

CONFERENCE PDF POSTER
High Prevalence of Primary Lamivudine and Nelfinavir Resistance in HIV-1-infected
Pregnant Women in the United States, 1998-2003
R Paredes, I Cheng, D Kuritzkes, et al
 (14 CROI)
 PDF Poster    Abstract
HIV Combination Therapy
ZDV/3TC vs DDI  ZDV/3TC/ABC    

3TC/ZDV

     Pharmacokinetics

            Journal Papers, Abstracts, and Commentaries

  FULL-TEXT ARTICLE
 Pharmacokinetics and antiretroviral activity of lamivudine alone or when coadministered
with zidovudine in human immunodeficiency virus type 1-infected pregnant women and
their offspring.
Moodley J, Moodley D, Pillay K, et al.
J Infect Dis 1998 Nov;178(5):1327-33
Paper		  

     Safety/Efficacy

              Journal Papers, Abstracts, and Commentaries

 
Prevention of Mother-to-Child Transmission of HIV-1 Through Breast-Feeding by
Treating Infants Prophylactically With Lamivudine in Dar es Salaam, Tanzania:
The Mitra Study.
Kilewo C, Karlsson K, Massawe A, et al 
J Acquir Immune Defic Syndr. 2008 Mar 13
 Abstract

FULL-TEXT ARTICLE
 Lamivudine- Zidovudine Combination  for Prevention of Maternal-Infant Transmission of HIV-1 
Mandelbrot L, et al
JAMA Vol 285; No 16; P 2083-2093
Paper

  

               Conference Reports, Abstracts, and Posters

  Zidovudine-lamivudine for Prevention of Mother to Child HIV-1 Transmission
(6RETRO)   
Abstract
 

3TC/NFV/ZDV

Safety/Pharmacokinetics/Efficacy

          Conference Reports, Abstracts, and Posters

  PACTG 353 A Phase I Study of Safety, Pharmacokinetics, and Antiviral Activity of
Combination Nelfinavir (NFV), ZDV, and 3TC in HIV-Infected Pregnant Women and
Their -Infants
 (7RETRO) 
Abstract		  

3TC/PI

              Journal Papers, Abstracts, and Commentaries

 

3TC+ PI dual therapy during pregnancy for PMTCT of HIV-1-naïve or pretreated women.
Gliga S, Clavel C, Alix A,
J Int AIDS Soc. 2012 Nov 11;15(6):18222.
 Abstract
HIV General Reports Challenges
       
            Journal Papers, Abstracts, and Commentaries
 
  Abacavir and Lamivudine Exposures during Pregnancy and Non-Defect Adverse Pregnancy Outcomes: Data from the Antiretroviral Pregnancy Registry.
 Vannappagari V, Koram N, Albano J, et al
J Acquir Immune Defic Syndr. 2014 Dec 2
 Abstract

FULL-TEXT PDF ARTICLE
 Lopinavir/Ritonavir versus Lamivudine peri-exposure prophylaxis to prevent HIV-1 transmission by breastfeeding:
the PROMISE-PEP trial Protocol ANRS 12174.
 Nagot N, Kankasa C, Meda N, et al
BMC Infect Dis. 2012 Oct 6;12(1):246
 Paper
HIV Adverse Events
       
            Journal Papers, Abstracts, and Commentaries
 
  Abacavir and Lamivudine Exposures during Pregnancy and Non-Defect Adverse Pregnancy Outcomes: Data from the Antiretroviral Pregnancy Registry.
 Vannappagari V, Koram N, Albano J, et al
J Acquir Immune Defic Syndr. 2014 Dec 2
 Abstract

 
Lamivudine Main Page Main New/Newsworthy  Home Page      

Lamivudine Perinatal Data
.